Papulopustular Rosacea: Clinical Trials

11 trials for Papulopustular Rosacea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 11
Phase 12Completed 2

Follow Papulopustular Rosacea: new trials by email Literature Review of Papulopustular Rosacea trials Research Report on Papulopustular Rosacea

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of TP-04 in Participants With Papulopustular Rosacea
Lotilaner Gel, 2.0%, Vehicle control gel - Papulopustular Rosacea
Phase 2CompletedTarsus Pharmaceuticals, Inc.372023-03-012023-11-24
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rifaximin, Placebo - Papulopustular Rosacea
Phase 2CompletedAlfasigma S.p.A.2162021-10-052024-04-24
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel - Rosacea, Papulopustular Rosacea
Phase 2CompletedHovione Scientia Limited2702017-10-302019-11-08
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
Secukinumab - Papulopustular Rosacea
Phase 1 / Phase 2CompletedAnne Chang242017-06-212020-02-05
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
FMX-103 1.5%, FMX-103 3%, Vehicle foam (0%) - Rosacea, Papulopustular Rosacea
Phase 2CompletedVyne Therapeutics Inc.2332015-09-012017-02-15
An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
Cromolyn Sodium, Normal Saline - Papulopustular Rosacea
Phase 1 / Phase 2CompletedUniversity of California, San Diego102013-08-012019-08-07
A Twelve Week Safety and Efficacy Study in Rosacea
omiganan, placebo - Papulopustular Rosacea
Phase 2CompletedMaruho Co., Ltd.2402013-03-012015-05-20
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
PAC-14028 cream 1%, Vehicle, Rozex gel 0.75% - Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Phase 2CompletedAmorepacific Corporation802013-02-012014-02-03
Open Label Pilot Study of Apremilast in Treatment of Rosacea
Apremilast - Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Phase 2CompletedJulian M. Mackay-Wiggan102010-06-012016-12-13
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Azelaic acid foam 15%, Vehicle foam - Papulopustular Rosacea
Phase 2CompletedLEO Pharma4012009-12-012020-03-31
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
Azelaic acid, Vehicle foam - Papulopustular Rosacea
Phase 2CompletedLEO Pharma832008-01-012020-04-07

Narrower conditions

Rosacea (11)  ·  Skin Diseases (1)  ·  Telangiectasis (1)  ·  cyclopia sequence (1)

Broader conditions

Skin and Connective Tissue Diseases (11)  ·  Skin Diseases (10)  ·  Cardiovascular Diseases (1)  ·  Vascular Diseases (1)

Interventions

Cromolyn Sodium (1)  ·  N-(1-(3,5-difluoro-4-methanesulfonylaminophenyl)ethyl)-3-(2-propyl-6-trifluoromethylpyridine-3-yl)acrylamide (1)  ·  Omiganan (1)  ·  Rifaximin (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  apremilast (1)  ·  azelaic acid (1)  ·  guselkumab (1)  ·  secukinumab (1)

Sponsors

LEO Pharma (2)  ·  Alfasigma S.p.A. (1)  ·  Amorepacific Corporation (1)  ·  Anne Chang (1)  ·  Hovione Scientia Limited (1)  ·  Julian M. Mackay-Wiggan (1)  ·  Maruho Co., Ltd. (1)  ·  Tarsus Pharmaceuticals, Inc. (1)  ·  University of California, San Diego (1)  ·  Vyne Therapeutics Inc. (1)

Countries

United States (8)  ·  Canada (1)  ·  Germany (1)  ·  South Korea (1)

Top investigators

Anne Chang, MD (1)  ·  BeomJoon Kim, Professor (1)  ·  Jose Trevejo, MD, PhD (1)  ·  Julian Mackay-Wiggan, MD, MS (1)  ·  Sunil S Dhawan, MD (1)  ·  Ulrich Mrowietz, MD (1)

Results publications

PMID 29396702